JCI insight · 2022
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant.
СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Seaman Michael S, Siedner Mark J, Boucau Julie, Lavine Christy L, Ghantous Fadi, Liew May Y, Mathews Josh I, Singh Arshdeep, Marino Caitlin, Regan James, Uddin Rockib, Choudhary Manish C, Flynn James P, Chen Geoffrey, Stuckwisch Ashley M, Lipiner Taryn, Kittilson Autumn, Melberg Meghan, Gilbert Rebecca F, Reynolds Zahra, Iyer Surabhi L, Chamberlin Grace C, Vyas Tammy D, Vyas Jatin M, Goldberg Marcia B, Luban Jeremy, Li Jonathan Z, Barczak Amy K, Lemieux Jacob E
Аннотация
Protective immunity against SARS-CoV-2 infection after COVID-19 vaccination may differ by variant. We enrolled vaccinated (n = 39) and unvaccinated (n = 11) individuals with acute, symptomatic SARS-CoV-2 Delta or Omicron infection and performed SARS-CoV-2 viral load quantification, whole-genome sequencing, and variant-specific antibody characterization at the time of acute illness and convalescence. Viral load at the time of infection was inversely correlated with antibody binding and neutralizing antibody responses. Across all variants tested, convalescent neutralization titers in unvaccinated individuals were markedly lower than in vaccinated individuals. Increases in antibody titers and neutralizing activity occurred at convalescence in a variant-specific manner. For example, among individuals infected with the Delta variant, neutralizing antibody responses were weakest against BA.2, whereas infection with Omicron BA.1 variant generated a broader response against all tested variants, including BA.2.